Protocol Ledger

NCT06502990 · Phase III · TERMINATED

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Interventional Phase III clinical trial protocol NCT06502990 sponsored by Amryt Pharma in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-23 Enrollment: 1 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06502990
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06502990
Protocol FieldVerified Registry Value
NCT IdentifierNCT06502990
Consolidated Lead SponsorAmryt Pharma
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment1 participants (ACTUAL)
Registered Start Date2025-05-23
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI